Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 205

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease: Zileuton: 5-LO pathway inhibition

Open access
Berger, W., De Chandt, M. T. M., Cairns, C. B. · 2007 · International Journal of Clinical Practice

Abstract

The 5-Lipoxygenase pathway results in the formation of leukotrienes, including leukotriene B(4) (LTB(4)), 5-oxo-6E,8Z,11Z,14Z-eicosatetranoic acid and the cysteinyl leukotrienes (LTC(4), LTD(4) and LTE(4)) and activates all four leukotriene receptors, BLT1, BLT2, cysLT(1) and cysLT(2). Zileuton is the only commercially available inhibitor of the 5-Lipoxygenase pathway. In a number of clinical trials, zileuton has been shown to improve airway function and inflammation, asthma symptom control and quality of life in asthmatics. Given the important role that leukotrienes play in airway inflammation, zileuton provides an additional therapeutic option in the management of chronic, persistent asthma, particularly those asthmatics with more severe disease. In addition, zileuton has shown promise in a number of other conditions, including upper airway inflammatory conditions, dermatological disease and chronic obstructive pulmonary disease. The development of new formulations, including a controlled release tablet formulation for b.i.d. dosing and an intravenous preparation for acute asthma exacerbations may enhance clinical utility and expand therapeutic indications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1742-1241.2007.01320.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 205

Metadata

Authors
Berger, W., De Chandt, M. T. M., & Cairns, C. B.
Venue
International Journal of Clinical Practice
Published
2007-03-22
Volume
61
Issue
4
Pages
663-676
ISSN
1368-5031 (ISSN-L)
OpenAlex
W1712101512
Cited by
205
References
3
FWCI
6.92
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease: Zileuton: 5-LO pathway inhibition. https://app.cochat.ai/papers/10.1111/j.1742-1241.2007.01320.x
The paper
Berger, W., De Chandt, M. T. M., & Cairns, C. B. (2007). Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease: Zileuton: 5-LO pathway inhibition. International Journal of Clinical Practice. https://doi.org/10.1111/j.1742-1241.2007.01320.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.